Next-Generation Cannabinoid Medicines

Kalytera’s drug candidates are cannabinoid and endocannabinoid-like compounds that strive to improve upon first-generation cannabis products and their analogues by increasing drug specificity while simultaneously reducing or eliminating unwanted side effects.

About Us

Kalytera is advancing a portfolio of non-psychoactive cannabinoid and endocannabinoid-like compounds that we believe will address important unmet market needs. Kalytera is developing both natural and synthetic products, with drug candidates that include:

  • Cannabidiol (“CBD”), a natural non-psychoactive cannabis constituent.
  • KAL436/9, proprietary synthetic derivatives of CBD that have been structurally modified to enhance solubility in water to improve potency.
  • KAL671, a proprietary form of the free fatty acid oleoyl-alphamethyl-serine.

By modifying cannabinoid molecules, and molecules which regulate the endogenous cannabinoid signaling system, Kalytera seeks to improve pharmacokinetics and increase potency, potentially allowing for the development of drug candidates with improved activity.

Development Programs

Preclinical studies support the continued investigation of Kalytera drug candidates in a range of conditions, including:

Our Team

Kalytera’s leadership includes pioneers in the field of cannabis research including Dr. Raphael Mechoulam, the discoverer of the endocannabinoid system, and Dr. Yossi Tam, an investigator at the Hebrew University and the Director of the Multidisciplinary Center on Cannabinoid Research. View our Scientific Advisory Board >>

Important Notice

Notice: We do not have approval from the U.S. Food and Drug Administration or any other governmental agency, whether in the U.S. or abroad, to sell or market any product to treat or cure any disease or condition, including our drug candidates that we hypothesize may, following further study, clinical trials and all required approvals, be used to treat Bone Fractures, Osteogenesis Imperfecta, Osteoporosis, or Osteoporosis in Prader-Willi syndrome. Our drug candidates have not completed the approval process (including, but not limited to clinical trials) that is required by the U.S. Food and Drug Administration. Our drug candidates have not been proven safe and effective and may not receive U.S. Food and Drug Administration approval. We do not currently sell any drug products or other treatments.


The mainstream medical establishment has begun to actively explore the use of cannabinoids for a variety of ailments.


Kalytera has in-licensed its proprietary drug candidates from Yissum; Yissum markets and licenses the inventions and intellectual property developed by Hebrew University.

Kalytera has entered into a collaboration with Ramot at Tel Aviv University to explore the potential of Kalytera drug candidates through preclinical research.

Kaltyera has in-licensed a novel transdermal drug delivery technology from Delivra; Delivra will help formulate Kaltyera drug candidates for delivery through the skin.